Promoter holding
64.27%
NL
Neuland Laboratories Ltd. - Due diligence report
A 360° intelligence report on Neuland Laboratories: trust score, financial health, credit view, compliance, directors, growth and distress s…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Neuland Laboratories — 360° Intelligence Report
Generated from MCA filings & public records80/100
Trust Score
Low Risk
Neuland Laboratories is assessed as Low Risk with a Trust Score of 80/100. Neuland Laboratories is an active public limited indian non-government company incorporated in 1984, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Neuland Laboratories Ltd. snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 3 open (1,091.88 cr) · 59 satisfied (2,289.23 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 11 | 48.0 cr |
| Sbicap Trustee Company Limited | 1 | 48.0 cr |
| Others | 8 | 48.0 cr |
| Bank Of India | 7 | 48.0 cr |
| Export-Import Bank Of India | 5 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PRASAD RAGHAVA MENON | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HOMI RUSTAM KHUSROKHAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAVI SHANKAR GOPINATH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PALLAVI JOSHI BAKHRU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMAMOHAN DAVULURI RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SAHARSH RAO DAVULURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUGATA SIRCAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUCHETH RAO DAVULURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SARADA BHAMIDIPATI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Abhijit Majumdar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHRISTOPHER CIMARUSTI M | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Abhijit Ajay Majumdar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- No disqualified or deactivated DINs.
- 6 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Neuland Laboratories Inc | Subsidiary Company | 74.00% |
| Neuland Laboratories Kk | Subsidiary Company | 74.00% |
Key managerial personnel: RAMAMOHAN DAVULURI RAO (Whole-time director) · SAHARSH RAO DAVULURI (Whole-time director) · SUCHETH RAO DAVULURI (Whole-time director) · Abhijit Majumdar (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 42+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.24 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence75/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 1,091.88 cr already registered.
- Compliance record supports lending.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events18 Nov 2025
Charge satisfied
Others
25 Sep 2025
Director ceased
RAVI SHANKAR GOPINATH
01 Aug 2025
Director appointed
RAVI SHANKAR GOPINATH (Director)
30 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
18 Mar 2025
Charge created
Others - 190.00 cr
23 Aug 2024
Charge satisfied
State Bank Of India
08 May 2024
Director ceased
BHARATI RAO
26 Apr 2024
Charge created
State Bank Of India - 95.00 cr
31 Mar 2024
Director ceased
PARAMPALLY VASUDEVA MAIYA
27 Nov 2023
Charge created
Axis Bank Limited - 2.71 cr
18 Oct 2023
Director appointed
Abhijit Ajay Majumdar (Cfo)
25 Sep 2023
Director ceased
HUMAYUN DHANRAJGIR
26 Jul 2023
Director ceased
PALLAVI JOSHI BAKHRU
Director ceased
SUGATA SIRCAR
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
12 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Colorcon | U01122GA1994PTC003308 | Goa, Goa, India |
| Pocl Enterprises | L52599TN1988PLC015731 | Chennai, Tamil Nadu, India |
| Athani Sugars Limited | U40109KA1995PLC017806 | Karnataka, Karnataka, India |
| Sukhjit Starch & Chemicals | L15321PB1944PLC001925 | Punjab, Punjab, India |
| K L J Polymers And Chemicals Limited | U24119DL1989PLC036883 | New Delhi, Delhi, India |
| Calderys | U02692MP2005PLC017865 | Katni, Madhya Pradesh, India |
| Jacpl | L52100UP2008PLC035862 | Gajraula, Uttar Pradesh, India |
| Laborate Pharmaceuticals India | U24239HR1990PLC030835 | Haryana, Haryana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Neuland Laboratories before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Neuland Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Neuland Laboratories - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Neuland Laboratories pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Neuland Laboratories - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Neuland Laboratories an active company?
Neuland Laboratories has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Neuland Laboratories financially healthy?
Neuland Laboratories has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Neuland Laboratories?
Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Neuland Laboratories?
Promoters hold a minority stake - exact percentages are in the full report. 12 active director(s) are on record.
Does Neuland Laboratories have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 59 earlier charge(s) stand satisfied.
Is Neuland Laboratories up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Neuland Laboratories?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
